Company intelligence / Profile preview
OncoTAb
North Carolina, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
OncoTAb's lead antibody hTAB004 (humanized TAB004) conjugated with radionuclides showed significant preclinical efficacy for imaging and reduction of tumor volume in triple negative breast cancer mouse models. The technology demonstrates potential for both sensitive cancer detection and targeted therapy, using fully humanized monoclonal antibodies, nanobodies, and peptides targeting tMUC1, but clinical development is still at the preclinical or discovery phase.[1][2]
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyRadionuclide drug conjugateNanobody therapySynthetic peptideBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on OncoTAb.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoTAb.